The Technical Analyst
PAVmed Inc [PAVMZ]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Medical - Devices
PAVmed Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-23.67% $0.0229
/ 25 apr 2024 @ 11:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 12.95 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Mar 30, 2023 |
| SharesOutstanding: | 565.63 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0099 - 0.0359 ( +/- 56.77%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-04 | O'neil Shaun | Sell | 25 935 | Common stock |
| 2022-02-22 | O'neil Shaun | Sell | 0 | Common stock |
| 2022-02-22 | O'neil Shaun | Sell | 195 108 | Employee stock option (right to buy) |
| 2022-02-22 | O'neil Shaun | Sell | 100 000 | Employee stock option (right to buy) |
| 2022-02-22 | O'neil Shaun | Sell | 75 000 | Employee stock option (right to buy) |
| INSIDER POWER |
|---|
| 99.83 |
| Last 14 transactions |
| Buy: 2 950 000 | Sell: 396 043 |
Forecast:
13:45 - $0.0200
Live Trading Signals (every 1 min)
Forecast
1: 12:15 - $0.0220
Forecast 2: 13:05 - $0.0200
Forecast 3: 13:45 - $0.0200
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0229 (-23.67% ) |
| Volume | 0.0267 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PAVMZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PAVMZ
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Latest News
2020-08-18 20:14:00 - Yahoo
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
Conference call to be held today at 4:30 p.m. Eastern timeNEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today reported financial results for the three and six months ended June 30, 2020 and provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (“Lucid”) and Solys Diagnostics Inc. (“Solys”).“The second quarter of 2020 and subsequent weeks constitute an unprecedented period of major accomplishments for PAVmed and its subsidiaries, despite significant Covid-19 headwinds in the late spring and early summer,” said Lishan Aklog, M...
2020-08-06 13:27:00 - Yahoo
PAVmed Secures $7 Million Convertible Note Financing
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has received approximately $7 million in gross proceeds from a private placement (the “Financing”) of Senior Convertible Promissory Notes with an existing institutional investor. Proceeds from the Financing will support the Company’s commercialization, regulatory and product development activities, including the commercialization of EsoGuard™/EsoCheck™ and CarpX™, its EsoGuard BE-1 and BE-2 clinical trials and for general working capital purposes.The Financing is led by an existing institutional investor who participated in senior convertible promissory note financings with similar terms in December 2018, November 2019, and April 2020...
2020-07-13 13:30:10 - Yahoo
PAVmed to Present at Maxim Group’s COVID-19 Webinar on July 16, 2020
NEW YORK, July 13, 2020 -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today.
2020-06-17 13:30:10 - Yahoo
PAVmed to Join the Russell 2000® and Russell 3000® Indexes
NEW YORK, June 17, 2020 -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the.
2020-06-15 13:30:10 - Yahoo
Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that medical diagnostics pioneer Stanley Lapidus, founder and former Chairman and CEO of Exact Sciences (EXAS), has joined its majority owned subsidiary, Lucid Diagnostics Inc. (“Lucid”), as a Strategic Advisor to assist with its commercial, regulatory, clinical trial and capital markets strategies. “I am thrilled to welcome Stan Lapidus as a Lucid Strategic Advisor and look forward to tapping into his vast wealth of knowledge, experience and wisdom as we advance EsoGuard and EsoCheck commercialization,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer and Lucid’s Executive Chairman.
2020-06-11 13:30:10 - Yahoo
PAVmed Subsidiary Lucid Diagnostics Receives Preliminary Payment Determination for EsoGuard™ Esophageal DNA Test
NEW YORK, June 11, 2020 -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that its.
2020-06-03 13:30:10 - Yahoo
PAVmed Collaborates with Canon on DisappEAR™ Pediatric Ear Tubes
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the Company and global manufacturer Canon Inc.’s United States manufacturing and technology center, Canon Virginia, Inc. (“Canon Virginia”), have executed a letter of intent (the “LOI”) to consummate a series of agreements to develop and utilize Canon Virginia’s commercial grade and scalable aqueous silk fibroin molding process to manufacture PAVmed’s DisappEAR molded pediatric ear tubes for commercialization. “We are very proud to partner with such a highly-respected leading global manufacturer as Canon to develop and commercialize our DisappEAR resorbable pediatric ear tubes,” said Lishan Aklog, M...
2020-05-21 20:00:10 - Yahoo
PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update
Conference call to be held today at 4:30 p.m. Eastern time NEW YORK, May 21, 2020 -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated,.
2020-05-11 13:30:10 - Yahoo
PAVmed to Hold Business Update Conference Call on May 21, 2020
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a business update conference call on Thursday, May 21, 2020 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s President and Chief Financial Officer, will discuss first quarter 2020 financial results.
2020-04-21 13:30:10 - Yahoo
PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has received 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) for its CarpX™ minimally invasive carpal tunnel device. The FDA determined that CarpX is “substantially equivalent to legally marketed predicates” and that PAVmed may market CarpX for “the minimally invasive isolation and incision/division of ligaments, tendons, or fascia such as the transverse carpal ligament for treatment of carpal tunnel syndrome.” The FDA reached this determination after reviewing detailed data from the Company’s successful CarpX clinical safety study performed in New Zealand.